Charles Schwab’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Charles Schwab’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,235	Closed	-$34.8K	–	3682
2023 Q2	$34.8K	Sell	19,235 -56,469	-75%	-$103K	﹤0.01%	3476
2023 Q1	$100K	Hold	75,704	–	–	﹤0.01%	3249
2022 Q4	$128K	Sell	75,704 -13,159	-15%	-$16.7K	﹤0.01%	3236
2022 Q3	$165K	Sell	88,863 -115,759	-57%	-$345K	﹤0.01%	3185
2022 Q2	$629K	Buy	204,622 +57,818	+39%	+$353K	﹤0.01%	2977
2022 Q1	$1.06M	Buy	+146,804	New	+$1.44M	﹤0.01%	2828

Other funds holding PRDS

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Charles Schwab's PRDS Position: Q3 2023 in Review

Charles Schwab sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 19,235 shares — an estimated $34.8K sold.

Charles Schwab first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $1.06M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Charles Schwab reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Charles Schwab sold 19,235 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $34.8K.
Charles Schwab first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Charles Schwab's Pardes Biosciences, Inc. Common Stock position peaked at $1.06M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.